V 0191Alternative Names: V-0191
Latest Information Update: 25 Aug 2015
At a glance
- Originator Pierre Fabre
- Class Antidementias
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Mild cognitive impairment
Most Recent Events
- 25 Aug 2015 Discontinued - Phase-II for Mild cognitive impairment in Austria, Belgium, Finland, France and Spain (PO)